Commentary
Generating randomized trial evidence to optimize treatment in the COVID-19 pandemic
Matthew P. Cheng, Todd C. Lee, Darrell H.S. Tan and Srinivas Murthy
CMAJ April 14, 2020 192 (15) E405-E407; DOI: https://doi.org/10.1503/cmaj.200438
Matthew P. Cheng
Division of Infectious Diseases (Cheng, Lee), Department of Medicine, and Division of Medical Microbiology (Cheng), Department of Laboratory Medicine, McGill University Health Centre; Clinical Trials Platform (Cheng, Lee), McGill Interdisciplinary Initiative in Infection and Immunity, Montréal, Que.; Division of Infectious Diseases (Tan) and MAP Centre for Urban Health Solutions (Tan), St. Michael’s Hospital; Department of Medicine (Tan), University of Toronto, Toronto, Ont.; Department of Pediatrics (Murthy), University of British Columbia, Vancouver, BC
MDCMTodd C. Lee
Division of Infectious Diseases (Cheng, Lee), Department of Medicine, and Division of Medical Microbiology (Cheng), Department of Laboratory Medicine, McGill University Health Centre; Clinical Trials Platform (Cheng, Lee), McGill Interdisciplinary Initiative in Infection and Immunity, Montréal, Que.; Division of Infectious Diseases (Tan) and MAP Centre for Urban Health Solutions (Tan), St. Michael’s Hospital; Department of Medicine (Tan), University of Toronto, Toronto, Ont.; Department of Pediatrics (Murthy), University of British Columbia, Vancouver, BC
MD MPHDarrell H.S. Tan
Division of Infectious Diseases (Cheng, Lee), Department of Medicine, and Division of Medical Microbiology (Cheng), Department of Laboratory Medicine, McGill University Health Centre; Clinical Trials Platform (Cheng, Lee), McGill Interdisciplinary Initiative in Infection and Immunity, Montréal, Que.; Division of Infectious Diseases (Tan) and MAP Centre for Urban Health Solutions (Tan), St. Michael’s Hospital; Department of Medicine (Tan), University of Toronto, Toronto, Ont.; Department of Pediatrics (Murthy), University of British Columbia, Vancouver, BC
MD PhDSrinivas Murthy
Division of Infectious Diseases (Cheng, Lee), Department of Medicine, and Division of Medical Microbiology (Cheng), Department of Laboratory Medicine, McGill University Health Centre; Clinical Trials Platform (Cheng, Lee), McGill Interdisciplinary Initiative in Infection and Immunity, Montréal, Que.; Division of Infectious Diseases (Tan) and MAP Centre for Urban Health Solutions (Tan), St. Michael’s Hospital; Department of Medicine (Tan), University of Toronto, Toronto, Ont.; Department of Pediatrics (Murthy), University of British Columbia, Vancouver, BC
MDCM MHScData supplements
Related Articles
- Lee, P. H. (2020). Sample sizes in COVID-19–related research. CMAJ, 192(17), E461. Accessed April 19, 2024. https://doi.org/10.1503/cmaj.75308.
- Tsang, J. L., Binnie, A., Farjou, G., Fleming, D., Khalid, M., & Duan, E. (2020). Participation of more community hospitals in randomized trials of treatments for COVID-19 is needed. CMAJ, 192(20), E555. Accessed April 19, 2024. https://doi.org/10.1503/cmaj.75585.
- Flamein, F., Gottrand, F., Patel, M. L., & Hankard, R. (2020). Impact of COVID-19 on pediatric clinical research in France. CMAJ, 192(21), E589. Accessed April 19, 2024. https://doi.org/10.1503/cmaj.75416.
- Malinowski, A. K., Snelgrove, J., & Okun, N. (2020). Excluding pregnancy from COVID-19 trials: Protection from harm or the harm of protection?. CMAJ, 192(23), E634. Accessed April 19, 2024. https://doi.org/10.1503/cmaj.75807.
- Cheng, M. P., Lee, T. C., Tan, D. H., & Murthy, S. (2020). Générer des données d’essais randomisés pour optimiser le traitement à l’ère de la pandémie de COVID-19. CMAJ, 192(42), E1296-E1298. Accessed April 19, 2024. https://doi.org/10.1503/cmaj.200438-f.
In this issue
Article tools
Respond to this article
Generating randomized trial evidence to optimize treatment in the COVID-19 pandemic
Matthew P. Cheng, Todd C. Lee, Darrell H.S. Tan, Srinivas Murthy
CMAJ Apr 2020, 192 (15) E405-E407; DOI: 10.1503/cmaj.200438
Related Articles
Cited By...
- Effects of allocation concealment and blinding in trials addressing treatments for COVID-19: A methods study
- Post-exposure Prophylaxis or Preemptive Therapy for SARS-Coronavirus-2: Study Protocol for a Pragmatic Randomized Controlled Trial
- Difficultes associees a levaluation des vaccins contre le SRAS-CoV-2 pendant la pandemie de COVID-19
- Challenges in evaluating SARS-CoV-2 vaccines during the COVID-19 pandemic
- Excluding pregnancy from COVID-19 trials: Protection from harm or the harm of protection?
- Impact of COVID-19 on pediatric clinical research in France
- Participation of more community hospitals in randomized trials of treatments for COVID-19 is needed